Clinical trials: Sarcoma,Soft Tissue, open to volunteers
Ovarian Cancer, Ovarian Carcinoma
Sequential CD146 and GPC3 CAR-T Cell Therapy in Advanced Ovarian Cancer
This is a multicenter, open-label Phase 1/2 clinical trial evaluating the safety and preliminary efficacy of sequentially administered CD146-targeted and GPC3-targeted CAR-T cell therapy in patients with advanced relapsed or…
- Conditions
- Ovarian Cancer, Ovarian Carcinoma, Ovarian Sarcoma, Ovarian Cancer Stage IV
- Trial name
- BAH2573-104 (NCT07067255)
- Testing
- GPC3 CD146 CAR-T cells
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Essen Biotech
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
This phase II trial studies how well low dose, reduced frequency nivolumab works in treating patients with cancer that cannot be removed by surgery (unresectable) or that has spread from where it first started (primary site) to…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
- Trial name
- NCT07576725
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- Uganda
- Volunteers
- 50 people
- Sponsor
- Fred Hutchinson Cancer Center
Refractory Solid Tumors, Relapsed Solid Tumors
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
The phase 1 primary objective is to determine the pediatric recommended phase 2 dose (RP2D) of PEEL-224 as a single agent (phase 1A) and in combination with vincristine and temozolomide (phase 1B).
- Conditions
- Refractory Solid Tumors, Relapsed Solid Tumors, Relapsed Neuroblastoma, Refractory Neuroblastoma
- Trial name
- PEEL-224 (NCT06721689)
- Testing
- PEEL-224, Vincristine, Temozolomide (TMZ)
- Where
- 7 sites in United States
- Volunteers
- 59 people
- Sponsor
- Theodore Laetsch
Sarcoma
Clinical Study of VG161 in the Treatment of Advanced Bone and Soft Tissue Sarcoma
This study plans to use 1.0×108PFU/day per cycle, intratumoral injection administration for 3 consecutive days, and 28 days as a cycle.
- Trial name
- NCT06126510
- Testing
- Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)
- Where
- China
- Volunteers
- 40 people
- Sponsor
- CNBG-Virogin Biotech (Shanghai) Ltd.
Leiomyosarcoma
A Study of Ivonescimab in People With Leiomyosarcoma
The purpose of this study is to find out if Ivonescimab is an effective and safe treatment that causes few or mild side effects for people with advanced/unresectable leiomyosarcoma.
- Trial name
- NCT07516925
- Testing
- Ivonescimab
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Malignant Peripheral Nerve Sheath Tumors
Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors
First, the investigators plan to use a retrospective analysis to determine the clinical landscape of neurofibromatosis (NF)1-associated malignant peripheral nerve sheath tumor (MPNST) and precursor lesions (e.g., atypical or…
- Trial name
- NCT03141021
- Where
- 13 sites in United States, Canada and 3 more
- Volunteers
- 1,050 people
- Sponsor
- Washington University School of Medicine
Sarcoma, Pediatric Brain Tumors
Pediatric Radiation Therapy Registry
The Johns Hopkins Pediatric Radiation Oncology Program is creating a registry that will capture the full 3D radiation dosimetry delivered to its pediatric patients to manage the quality of care provided, as well as to examine the…
- Trial name
- NCT07129317
- Where
- 2 sites in United States
- Volunteers
- 5,000 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Soft Tissue Sarcoma
Investigative Analysis of Soft Tissue Sarcoma Clinical Trials: An Observational Study
Generally, specific demographic cohorts exhibit higher participation rates in medical research, yet there exists a scarcity of research elucidating the trial attributes impacting the engagement of these particular demographics.
- Trial name
- NCT06264505
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
HIV, Kaposi Sarcoma Herpesvirus -Associated Multicentric Castleman Disease
New Approaches for the Diagnosis of Lymphoma and Multicentric Castleman Disease
Persons living with HIV (PLWH) in sub-Saharan Africa (SSA), lymphadenopathy often portends one of a number of life-threatening diseases including tuberculosis, lymphoma, and multicentric Castleman disease (MCD).
- Conditions
- HIV, Kaposi Sarcoma Herpesvirus -Associated Multicentric Castleman Disease, Hodgkin Lymphoma, Non-Hodgkin Lymphoma
- Trial name
- NCT07793006
- Testing
- Lymph Node or Core Needle Biopsy, Fine Needle Aspiration, Tiny Isothermal Nucleic acid Amplification System (TINY)
- Where
- Malawi
- Volunteers
- 500 people
- Sponsor
- Indiana University
Ewing Sarcoma, Osteosarcoma
Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas
The purpose of this study is to better understand how safe and effective the drug cabozantinib in combination with high-dose ifosfamide is in the treatment of children and adults with relapsed/refractory sarcomas.
- Conditions
- Ewing Sarcoma, Osteosarcoma, Sarcomas
- Trial name
- NCT06156410
- Testing
- Cabozantinib
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Children's Hospital of Philadelphia
Relapsed or Refractory Pediatric Malignant Solid Tumors (Including Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma, Osteosarcoma)
Liposomal Irinotecan, Vincristine, Temozolomide, and Anlotinib for R/R Pediatric Solid Tumors
This is a prospective, single-center, single-arm interventional trial conducted at Tianjin Medical University Cancer Institute and Hospital.
- Trial name
- NCT07444918
- Testing
- Liposomal Irinotecan, Vincristine, Temozolomide, and Optional Anlotinib
- Volunteers
- 33 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Sarcoma, Synovial, Sarcoma,Soft Tissue
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
A Phase I/II Dose Escalation, Safety and Efficacy Study of HBI 0201-ESO TCRT (anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes) Given by Infusion to Patients with NY-ESO-1 -Expressing Metastatic Cancers
- Conditions
- Sarcoma, Synovial, Sarcoma,Soft Tissue, Melanoma Stage IV, Triple Negative Breast Cancer
- Trial name
- NCT05296564
- Testing
- CYCLOPHOSPHAMIDE and FLUDARABIN, Cyclophosphamide, HBI 0201-ESO TCRT
- Where
- Israel
- Volunteers
- 3 people
- Sponsor
- Hadassah Medical Organization
Lung Cancer, Liver Cancer
Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
This trial is designed to investigate the safety, response rates and survival outcomes of patients with advanced solid tumors by infusion of CTLA4, PD1 and PDL1 antibodies combination through venous (IV), artery (IA) or…
- Conditions
- Lung Cancer, Liver Cancer, Colorectal Cancer, Pancreas Cancer
- Trial name
- NCT05187338
- Testing
- ipilimumab +pembrolizumab +durvalumab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Soft Tissue Sarcoma
A Multicenter Phase II Clinical Trial Evaluating 68Ga-HX01 Injection for PET/CT Imaging
soft tissue sarcoma
- Trial name
- NCT07920835
- Testing
- 68Ga-HX01 Injection Solution
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Hexin (Suzhou) Pharmaceutical Technology Co., Ltd
Lung Non-Small Cell Carcinoma, Mediastinal Neoplasm
Phase II Trial of Lung Chemoemobolization
This phase II trial evaluates how well transarterial chemoembolization (TACE) works for treating patients with non-small cell lung cancer or lung metastases.
- Conditions
- Lung Non-Small Cell Carcinoma, Mediastinal Neoplasm, Pleural Neoplasm, Lung Metastases From Any Primary
- Trial name
- NCT05672108
- Testing
- Computed Tomography, Ethiodized Oil, Mitomycin
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- City of Hope Medical Center
Ewing Sarcoma
Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)
The main objectives of this trial are to determine the recommended dose for expansion of xaluritamig (dose confirmation part only) and to determine the safety and tolerability of xaluritamig in adult, adolescent and pediatric…
- Trial name
- NCT07297979
- Testing
- Xaluritamig
- Where
- 13 sites in United States, Australia
- Volunteers
- 50 people
- Sponsor
- Amgen
PDAC
Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With Metastatic or Locally Advanced PDAC
This is an open-label, multi-centre, single-arm Phase 1/2 clinical trial of the safety, expansion, persistence and clinical activity of a set of engineered autologous T cells products each capable of recognizing a specific…
- Trial name
- NCT07145450
- Testing
- ANOC-001 (TCR-T cells targeting KRAS G12V mutation presented by specific HLA alleles), ANOC-002 (TCR-T cells targeting KRAS G12V mutation presented by specific HLA alleles), ANOC-003 (TCR-T cells targeting KRAS G12D mutation presented by specific HLA alleles)
- Where
- 10 sites in Denmark, Germany and 2 more
- Volunteers
- 96 people
- Sponsor
- Anocca AB
Bone Sarcoma, Soft Tissue Sarcoma
Evaluation of Tumor Resection Guided by Intraoperative Indocyanine Green Dye Fluorescence Angiography in Patients With Sarcoma
This study evaluates the effectiveness of intraoperative indocyanine green dye and fluoroscopic technology in confirming negative margins after tumor removal.
- Trial name
- NCT06409013
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Mayo Clinic
Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
This study is being done to collect tissue samples to test how accurately a tumor response platform, Elephas, can predict clinical response across multiple types of immunotherapies, chemoimmunotherapy and tumor types.
- Conditions
- Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Cervical Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
- Trial name
- ELEPHAS-04 (NCT06349642)
- Testing
- Biospecimen Collection, Tissue Collection
- Where
- 3 sites in United States
- Volunteers
- 324 people
- Sponsor
- Mayo Clinic
NSCLC, SCLC
Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
This study is an exploratory study, and all the drugs involved are listed drugs. The dosage of mirabetron is selected according to the basis of previous research.
- Conditions
- NSCLC, SCLC, Colorectal Cancer, Pancreas Cancer
- Trial name
- NCT06534762
- Testing
- Mirabegron
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Zhejiang Provincial People's Hospital